rs33946267

chr11-5225678-C-Achr11-5225678-C-Gchr11-5225678-C-T

• Frequency: Genomes: not found (cov: 33)
• Consequence: HBB NM_000518 stop_gained
• Clinical Significance: Pathogenic criteria provided, multiple submitters, no conflicts P:7
• Conservation: PhyloP100: 4.94

ACMG classification

Verdict is Pathogenic. Variant got 17 ACMG points.

• PVS1: Loss of function variant, product does not undergo nonsense mediated mRNA decay. There are 70 pathogenic variants in the truncated region.
• PM2: Very rare variant; Number of alleles below threshold, Median coverage is 33.
• PP5: Variant 11:5225678-C>A is Pathogenic according to our data. Variant chr11-5225678-C-A is described in ClinVar as [Pathogenic]. Clinvar id is 15404. Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr11-5225678-C-A is described in Lovd as [Pathogenic].

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	MANE	UniProt
HBB	NM_000518.5	c.364G>T	p.Glu122Ter	stop_gained	3/3	ENST00000335295.4

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	#exon/exons	TSL	MANE	Appris	UniProt
HBB	ENST00000335295.4	c.364G>T	p.Glu122Ter	stop_gained	3/3	1	NM_000518.5	P1
HBB	ENST00000647020.1	c.364G>T	p.Glu122Ter	stop_gained	3/3			P1
HBB	ENST00000475226.1	n.296G>T		non_coding_transcript_exon_variant	2/2	2
HBB	ENST00000633227.1	c.*180G>T		3_prime_UTR_variant, NMD_transcript_variant	3/3	3

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD4 exome AF: 0.00000137 AC: 2 AN: 1461810 Hom.: 0 AF XY: 0.00000138 AC XY: 1 AN XY: 727216

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 0.00000180

Gnomad4 OTH exome AF: 0.00

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:7

Revision: criteria provided, multiple submitters, no conflicts

LINK:

Submissions by phenotype

Dominant beta-thalassemia Pathogenic:2

Pathogenic, criteria provided, single submitter	clinical testing	Women's Health and Genetics/Laboratory Corporation of America, LabCorp	May 06, 2022	Variant summary: HBB c.364G>T (p.Glu122X, also reported as p.Glu121X) is located in exon 3 (i.e. in the last exon) of the HBB gene. The current variant results in a premature termination codon that is not expected to cause nonsense mediated decay (NMD), but is predicted to cause a C-terminal truncation, removing a part of the 147 amino acid long protein. A truncation downstream of this position has been classified as pathogenic for dominant B-THAL by our laboratory. The variant was absent in 282706 control chromosomes (gnomAD). c.364G>T has been reported in the literature in multiple individuals affected with considerable variation in phenotype, ranging from mild anemia to severe hemolytic anemia with splenomegaly (e.g. Kazazian_1986, Thein_1990, Giordano_1998). The variant segregated with the phenotype in a dominant manner, and the presence of inclusion bodies was also noted in several cases. In at least one of these reported individuals the variant likely occurred as a de novo event (Kazazian 1986). A publication reported the presence of a truncated protein product from a patient, however the amount of the truncated protein was very low, suggesting that this beta-globin variant is highly unstable and is mostly degraded soon after translation, although the presence of the truncated protein product, might also explain the presence of the frequently reported Heinz bodies (Adams_1990). These data indicate that the variant is very likely to be associated with disease. Four ClinVar submitters have assessed the variant since 2014: all four classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic for dominant B-THAL. -
Pathogenic, no assertion criteria provided	literature only	OMIM	Jun 03, 2010	- -

beta Thalassemia Pathogenic:2

Pathogenic, no assertion criteria provided	clinical testing	Counsyl	Jan 30, 2018	- -
Pathogenic, no assertion criteria provided	clinical testing	Natera, Inc.	Jan 22, 2020	- -

not provided Pathogenic:2

Pathogenic, criteria provided, single submitter	clinical testing	Quest Diagnostics Nichols Institute San Juan Capistrano	Feb 21, 2017	- -
Pathogenic, criteria provided, single submitter	clinical testing	ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories	May 06, 2021	The HBB c.364G>T; p.Glu122Ter variant (also known as Glu121Ter when numbered from the mature protein or as Codon 121 (G->T); rs33946267) is reported in the literature in multiple individuals with clinical features varying from mild microcytic anemia to hemolytic anemia with splenomegaly and inclusion bodies (Divoka 2016, Fei 1989, Giordano 1998, Indrak 1992, Kazazian 1986, Stamatoyannopoulos 1974, Thein 1990, HbVar and references therein). In at least one severely affected individual, this variant was not found in either parent and thus appears to have arisen de novo (Kazazian 1986). The p.Glu122Ter variant was reported in early studies to segregate in several families with a dominant form of beta-thalassemia with inclusion bodies (Fei 1989, Giordano 1998, Stamatoyannopoulos 1974, Thein 1990). However, later observations in heterozygous individuals with hematology consistent with beta-thalassemia trait suggested this variant may exhibit a more typical recessive inheritance pattern, but with a clinical presentation possibly made more severe due to additional genetic or environmental factors (Divoka 2016, Giordano 1998, Indrak 1992). This variant results in a premature termination codon in the last exon of the HBB gene. While this may not lead to nonsense-mediated decay, it is expected to create a truncated protein lacking 26 amino acids, several of which are essential for heme binding (Thein 1990). Based on available information, this variant is considered to be pathogenic. References: HbVar link to p.Glu122Ter: http://globin.bx.psu.edu/cgi-bin/hbvar/query_vars3?mode=output&display_format=page&i=951 Divoka M et al. Molecular Characterization of ß-Thalassemia in the Czech and Slovak Populations: Mediterranean, Asian and Unique Mutations. Hemoglobin. 2016 Jun;40(3):156-62. Fei YJ et al. One form of inclusion body beta-thalassemia is due to a GAA----TAA mutation at codon 121 of the beta chain. Blood. 1989 Mar;73(4):1075-7. Giordano PC et al. Phenotype variability of the dominant beta-thalassemia induced in four Dutch families by the rare cd121 (G-->T) mutation. Ann Hematol. 1998 Dec;77(6):249-55. Indrak K et al. Molecular characterization of beta-thalassemia in Czechoslovakia. Hum Genet. 1992 Feb;88(4):399-404. Kazazian HH Jr et al. Characterization of a spontaneous mutation to a beta-thalassemia allele. Am J Hum Genet. 1986 Jun;38(6):860-7. Stamatoyannopoulos G et al. Inclusion-body beta-thalassemia trait. A form of beta thalassemia producing clinical manifestations in simple heterozygotes. N Engl J Med. 1974 Apr 25;290(17):939-43. Thein SL et al. Molecular basis for dominantly inherited inclusion body beta-thalassemia. Proc Natl Acad Sci U S A. 1990 May;87(10):3924-8. -

Hb SS disease Pathogenic:1

Pathogenic, criteria provided, single submitter

clinical testing

Baylor Genetics

-

- -

Computational scores

Source: dbNSFP v4.3

Name

Calibrated prediction

Score

Prediction

BayesDel_addAF

Pathogenic

0.60

D

BayesDel_noAF

Pathogenic

0.32

Cadd

Pathogenic

42

Dann

Uncertain

0.99

Eigen

Pathogenic

0.76

Eigen_PC

Uncertain

0.49

FATHMM_MKL

Uncertain

0.92

D

MutationTaster

Benign

1.0

D

Vest4

0.46

GERP RS

4.7

Splicing

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs33946267; hg19: chr11-5246908;